Skip to content
Delayed ~15 min

VRTX Vertex Pharmaceuticals

Permanent stock page ↗

Health Care · S&P 500 · Nasdaq 100

Next earnings: not announced yet

What 36 analyst firms say about Vertex Pharmaceuticals: their latest ratings, price targets and how far the stock is from them. How it works

542.50 USD−6.54 (−1.19%) today
Price as of 5 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+5.7%to the avg target 573.28 USD+30.78 USD
Buy 30 · Hold 6 · Sell 1

37 rated views · 38 analyst/firm records · 36 firms

Latest report3 Nov 2026avg report date 20 Jul
Target rangeLowest to highest analyst target, not a forecast

Radar score

  • S&P 500 · Top Picks · 6MBelow the Radar threshold of 8052
  • S&P 500 · Safest consensus · 6MBelow the Radar threshold of 8067
Other indices (1)
  • Nasdaq 100 · Top Picks · 6MBelow the Radar threshold of 8041
  • Nasdaq 100 · Safest consensus · 6MBelow the Radar threshold of 8065

Recent analyst activity · last 90 days

Our tracked history has 28 reports on VRTX from 19 analyst firms in the last 90 days (36 firms in the past year).

Comparing each firm's latest target with its previous one: 11 raised their price target, 1 lowered it, 2 left it unchanged and 1 has its first observed target in the past year.

No firm's latest available rating differs from its previous one.

Latest observed target change: Barclays raised its target from $617.00 (set 5 Aug 2026) to $626.00 on 4 Nov 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
ArgusJasper HellwegBuy21 Aug 2026—
BairdBrian P SkorneySell7 Jul 2026350.00 USD
Bank of America SecuritiesYing HuangBuy10 Mar 2026598.00 USD
BarclaysEliana MerleBuy5 Aug 2026617.00 USD
BernsteinJeffrey WalchBuy29 Jul 2026608.00 USD
BernsteinWilliam PickeringBuy29 Jul 2026—
BMO Capital MarketsEvan SeigermanBuy13 Jul 2026600.00 USD
Canaccord GenuityWhitney IjemHold4 Aug 2026442.00 USD
Cantor FitzgeraldCarter GouldBuy4 Aug 2026595.00 USD
CitigroupGeoff MeachamBuy7 Jul 2026585.00 USD
DaiwaUnnamed analystBuy11 Aug 2026556.00 USD
DBSNico ChenBuy13 Jan 2026480.00 USD
Erste GroupHans EngelHold25 Jun 2026—
Evercore ISICory KasimovBuy4 Aug 2026600.00 USD
Goldman SachsSalveen RichterBuy22 Oct 2026654.00 USD
GuggenheimDebjit ChattopadhyayBuy2 Jun 2026546.00 USD
H.C. WainwrightAndrew S FeinBuy4 Aug 2026641.00 USD
JefferiesAkash TewariBuy8 Jul 2026640.00 USD
JPMorganJessica FyeBuy11 Sep 2026560.00 USD
Leerink PartnersDavid RisingerBuy21 Sep 2026594.00 USD
Maxim GroupNaz RahmanBuy18 Mar 2026575.00 USD
Morgan StanleyTerence FlynnBuy1 Sep 2026665.00 USD
NeedhamJoseph R StringerHold1 Jun 2026—
OppenheimerJay OlsonBuy10 Mar 2026600.00 USD
Raymond JamesChristopher RaymondHold19 Oct 2026—
RBC Capital MarketsBrian AbrahamsBuy8 Oct 2026576.00 USD
RedburnSteven K ChesneyBuy5 Aug 2026580.00 USD
ScotiabankLouise ChenBuy26 Oct 2026558.00 USD
StifelUnnamed analystHold3 Nov 2026563.00 USD
TD CowenPhil NadeauBuy23 Sep 2026550.00 USD
TruistDanielle BrillBuy5 Aug 2026565.00 USD
UBSAshwani VermaBuy13 Jul 2026Conflicting reports · excluded
UBSMichael YeeBuy28 Sep 2026615.00 USD
Weiss RatingsUnnamed analyst—16 Oct 2026—
Wells FargoMohit BansalBuy19 Mar 2026550.00 USD
William BlairMyles R MinterBuy13 Oct 2026—
Wolfe ResearchAndy G ChenBuy7 Jul 2026562.00 USD
Data feed RESEARCHResearch TeamHold12 Feb 2026Conflicting reports · excluded

Partial coverage · checked 6 Nov (6 Nov 2026, 04:04 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.